Bamlanivimab and etesevimab, administered together, are authorized in the United States for the treatment of mild-to-moderate COVID-19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19 ...

FDA revised the EUA for bamlanivimab and etesevimab, administered together, to include emergency use as post-exposure prophylaxis (prevention) for COVID-19 in patients who are at high risk for...

2025年3月1日 · Here, we developed a broad-spectrum and affinity-mature antibody design (BAADesign) procedure to design CB6, enabling it to bind to the receptor-binding domains (RBDs) of multiple important Omicron subvariants, including the recent variant KP.2. Structural analysis confirmed the desired CB6-RBD interactions.

2023年1月30日 · Etesevimab is a human recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor-binding domain. Etesevimab is commonly labeled as LY-CoV016 or as JS016. Neutralizing monoclonal antibodies against SARS-CoV2 are available as 2 combination products.

2021年7月14日 · Two such neutralizing monoclonal antibodies, bamlanivimab and etesevimab, were isolated from convalescent plasma obtained from patients with Covid-19 in the United States and China, respectively...

Bamlanivimab and etesevimab injection is used in certain non-hospitalized adults, children, and infants including newborns, and who have certain medical conditions that make them at higher risk for developing severe COVID-19 symptoms, including hospitalization or death:

埃特司韦单抗（JS016）是由中科院微生物所与上海君实生物联合开发的治疗性抗体新药，具有独特的靶向性，可针对新冠病毒精准进攻，能阻止病毒进入细胞，快速产生作用。 在国际上，埃特司韦单抗的双抗体疗法已被分配超过50万剂用于紧急使用，在美国、意大利等15个国家和地区获得紧 …

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in...

2024年12月16日 · Omicron SARS-CoV-2 variant has become the dominant variant in the United States; antiviral resistance data show that bamlanivimab and etesevimab are unlikely to retain activity against Omicron.

In the phase 2/3 BLAZE-1 trial, bamlanivimab and etesevimab together reduced coronavirus disease 2019 (COVID-19)–related hospitalizations and any-cause mortality in ambulatory patients. Herein, we assess the impact of bamlanivimab and etesevimab ...